SEMAX

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), approved in Russia as a nootropic and neuroprotective agent and used clinically for stroke recovery, cognitive impairment, and ischemic brain injury. It is one of the longest-clinically-used peptides in the Russian medical system and has substantial post-market clinical experience but limited Western RCT replication. Important regulatory update: Semax came off the FDA's Category 2 bulk-substances list in April 2026 because the nominations were withdrawn by the nominators, and at its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted to recommend it for the 503A compounding list — an advisory vote only, with rulemaking not expected before late 2027.

What is Semax and how does the ACTH(4-10)-derived mechanism work?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment with N-terminal modifications for stability and intranasal bioavailability, proposed to act through multiple mechanisms: BDNF (brain-derived neurotrophic factor) upregulation, melanocortin receptor modulation, neurotransmitter system effects (dopaminergic, serotonergic), and direct neuroprotective effects against ischemic injury. The intranasal route allows direct nose-to-brain delivery, bypassing the blood-brain barrier and limiting systemic exposure.

Evidence level: approved in Russia (stroke, cognitive disorders); preclinical extensive (neuroprotection, BDNF); Western Phase 2/3 RCT limited

What does the research show for Semax?

Russian clinical practice has used Semax for ischemic stroke recovery, transient ischemic attack, cognitive impairment, and ADHD in pediatric populations, with substantial post-market clinical experience accumulated over 30+ years. Preclinical studies have shown BDNF upregulation, neuroprotection in stroke models, and effects on cognitive performance markers in rodents. Western-standard Phase 2/3 RCT data is limited; the strongest evidence base comes from Russian clinical use rather than blinded controlled trials.

Evidence level: russian clinical (approved use, decades of practice); preclinical extensive; Western RCT limited

How does Semax compare to other nootropic peptides?

Semax sits in the Russian-developed cognitive peptide cluster alongside Selank (anxiolytic) and N-Acetyl Semax Amidate (extended-stability Semax analog), distinguished by its primary cognitive enhancement and neuroprotection positioning.

What are the documented side effects of Semax?

Side effects in Russian clinical use are generally mild — occasional mild irritation of nasal mucosa with intranasal administration, transient headache, and rare reports of mild stimulation effects. The favorable safety profile is consistent with the ACTH-fragment origin and intranasal delivery limiting systemic exposure. Long-term safety has been observed in Russian clinical practice over decades with the caveats that apply to non-blinded clinical use.

Evidence level: russian clinical safety record (decades); Western RCT safety data limited

What is the regulatory status of Semax?

Semax is approved for medical use in Russia for ischemic stroke recovery, transient ischemic attack, and cognitive disorders, but is not approved by the FDA, EMA, or other major Western regulators. In April 2026 the FDA removed semax (as semax acetate) from its Category 2 "significant safety risks" bulk-substances list — a change the FDA attributed to the original nominations being withdrawn by the nominators, not a safety clearance, and one that did not add semax to Category 1 or authorize compounding. At its July 23–24, 2026 meeting the FDA's Pharmacy Compounding Advisory Committee voted 8–5 (one abstention) to recommend semax for the 503A compounding list — one of six of seven peptides recommended over FDA reviewers' objections. The vote is advisory only: pharmacies cannot legally compound semax under 503A until the FDA completes formal rulemaking, which is not expected before late 2027, and the agency may decline. Current status in FDA peptide regulation 2025–2026 timeline.

Sources: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights; PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

Why does Semax vendor verification matter?

Semax synthesis is mature and widely available in the research-grade market, but the structural similarity between Semax (Met-Glu-His-Phe-Pro-Gly-Pro) and N-Acetyl Semax Amidate (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂) creates mislabeling risk — vendors occasionally sell one as the other. Mass spectrometry identity confirmation distinguishes the two definitively. Intranasal formulations have additional stability and excipient considerations not addressed by basic peptide HPLC. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Semax vendors?

Peptigrity collects independent third-party Certificates of Analysis for Semax from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the cross-shop dataset. Tests come from labs including Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Semax do?

Semax is researched and clinically used in Russia for cognitive enhancement, ischemic stroke recovery, and neuroprotection, with proposed mechanisms including BDNF upregulation and effects on multiple neurotransmitter systems. Russian clinical evidence base is substantial; Western Phase 2/3 RCT evidence is more limited.

Is Semax legal to purchase?

Semax is approved for medical use in Russia and is legal to purchase as a research chemical for laboratory use in most other jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. The April 2026 Category 2 removal (attributed to withdrawn nominations) and the July 2026 PCAC recommendation are steps toward a possible future compounding pathway, but neither authorizes compounding today — that requires FDA rulemaking not expected before late 2027. Country breakdown in peptide legal status guide.

When will the FDA decide on Semax?

The PCAC has already reviewed Semax: at its July 23–24, 2026 meeting it voted 8–5 (one abstention) to recommend adding Semax to the 503A bulks list, over the objection of FDA's own reviewers. That recommendation is advisory, not a rule — the FDA must complete formal rulemaking (realistically late 2027 at the earliest) before compounding is lawful, and it may decline. The PCAC will evaluate historical safety data and clinical utility to make a recommendation on whether Semax should be added to the 503A bulks list. Track developments in FDA peptide regulation 2025–2026 timeline.

Source: PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

How does Semax differ from N-Acetyl Semax Amidate?

N-Acetyl Semax Amidate is Semax with N-terminal acetylation and C-terminal amidation modifications that extend half-life and improve bioavailability. They are different molecules with related effects; the modified analog has longer activity per dose. Some research-grade vendors sell one mislabeled as the other.

How can I verify a Semax vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass spec is essential to distinguish Semax from N-Acetyl Semax Amidate and from related ACTH-fragment peptides. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Semax dose?

No. Peptigrity is an independent review platform, not a medical authority. Russian clinical protocols for stroke recovery and cognitive indications vary; intranasal dosing is the primary clinical route. Anyone considering Semax use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Semax is approved for medical use in Russia but is not approved by the FDA or other major Western regulators. It was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review in July 2026. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.